Quarterly report pursuant to Section 13 or 15(d)

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

v3.20.2
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Jun. 30, 2020
Dec. 31, 2019
Current assets    
Cash and cash equivalents $ 122,359 $ 50,412
Marketable securities - available-for-sale debt securities 296,629 39,130
Other current assets and prepaid expenses (including current portion of clinical materials) 39,099 30,947
Total current assets 458,087 120,489
Restricted cash 4,324 4,496
Clinical materials 1,744 2,503
Operating lease right-of-use assets, net of accumulated amortization 18,892 20,789
Property, plant and equipment, net of accumulated depreciation of $26,100 (2019: $23,649) 27,020 31,068
Intangibles, net of accumulated amortization 2,134 2,198
Total assets 512,201 181,543
Current liabilities    
Accounts payable 8,766 6,357
Operating lease liabilities, current 2,493 2,493
Accrued expenses and other accrued liabilities 23,836 23,363
Deferred revenue, current 3,464 2,128
Total current liabilities 38,559 34,341
Operating lease liabilities, non-current 20,814 22,966
Deferred revenue, non-current 44,651  
Other liabilities, non-current 592 598
Total liabilities 104,616 57,905
Stockholders' equity    
Common stock - Ordinary shares par value ?0.001, 1,038,249,630 authorized and 927,668,946 issued and outstanding (2019: 785,857,300 authorized and 631,003,568 issued and outstanding) 1,324 943
Additional paid in capital 928,777 585,623
Accumulated other comprehensive loss (8,805) (7,264)
Accumulated deficit (513,711) (455,664)
Total stockholders' equity 407,585 123,638
Total liabilities and stockholders' equity $ 512,201 $ 181,543